IACTA Pharmaceuticals | 135 followers on LinkedIn. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute … Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Nasdaq 100. Its products include DSF100, Probudur, Epoladerm and … VRPX: Virpax Pharmaceuticals, Inc. - Earnings Announcements. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute … VRPX updated stock price target summary. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Overview Earnings Dividend Ownership. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for … About Virpax Pharmaceuticals. Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Virpax Pharmaceuticals Inc Virpax Pharmaceuticals, Inc. operates as a biotech company. Sell. About Virpax Pharmaceuticals. Insider buying vs selling Have Virpax Pharmaceuticals Inc insiders been buying or selling? Return from IPO: -51.4%. DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): IPO19.02.2021 / 22:07 The issuer is solely responsible for the content of this announcement.Virpax Pharmaceuticals Announces Closing of Initial Public OfferingWEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in … Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. Virpax Pharmaceuticals Inc. … 333-249417 Registration No. Its products include DSF100, Probudur, Epoladerm and NES100. Here's what we know — and how to buy stocks when it launches. Stay up to date with lastest Earnings Announcements for Virpax Pharmaceuticals, Inc. from Zacks Investment Research Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Changing the way we manage pain. This page provides a brief financial summary of Virpax Pharmaceuticals Inc as well as the most significant critical numbers from each of its financial reports. About Virpax Pharmaceuticals Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and … Follow Virpax Pharmaceuticals's earnings. Virpax Pharmaceuticals, Inc. is a biopharmaceutical company. View the live Virpax Pharmaceuticals Inc share price chart to track performance. Virpax Pharmaceuticals Inc. 101 Lindenwood Drive, Suite 225. Virpax is developing branded pharmaceutical product candidates for pain management by using … Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) | 1,498 followers on LinkedIn. Virpax Pharmaceuticals, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): Miscellaneous23.02.2021 / 14:00 The issuer is solely responsible for the content of this announcement.Virpax Begins IND Enabling Studies of Envelta(TM)WEST CHESTER, PA / ACCESSWIRE / February 23, 2021 / Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that … Reinventing pain relief. Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced preclinical results of MMS019, its anti-viral product candidate for respiratory viruses. Virpax Pharmaceuticals Inc. SEC filings breakout by MarketWatch. PROSPECTUS Filed Pursuant to Rule 424 (b) (4) Registration No. About Virpax Pharmaceuticals. Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Its products include DSF100, Probudur, Epoladerm and NES100. Email: accounts-payable@virpaxpharma.com . Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. As of Mar 30, 2021, the company held over 0.2 million shares (or … Buy. Virpax Pharmaceuticals Priced, Nasdaq: VRPX. Their stock opened with $10.00 in its Feb 16, 2021 IPO. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) has 1 current employee profile, Founding Chairman & CEO Anthony P Mack. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in Its products include Epoladerm, OSF200, Probudur, NES100, PES200 and MMS019. About Virpax Pharmaceuticals. Virpax is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and … The stock’s price range for the 52-week period managed to maintain the performance between $3.79 and $8.24. Virpax Pharmaceuticals, Inc. Common Stock, also called Virpax Pharmaceuticals, is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. Term. The term of this Agreement is for one (1) year from the Effective Date. Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. Virpax is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Virpax Pharmaceuticals Inc. (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No. Find the latest Virpax Pharmaceuticals, Inc. (VRPX) stock discussion in Yahoo Finance's forum. Presently, Virpax Pharmaceuticals Inc. shares are logging -37.62% during the 52-week period from high price, and 35.62% higher than the lowest price point for the same timeframe. Virpax Pharmaceuticals Description. Virpax shall reimburse such approved expenses within thirty (30) days of receipt of Consultant’s accurate written request for reimbursement. The Company intends to deliver this formulation using a preassembled device and cartridge to propel Spray formulation into the nose. Sabby Management, LLC is the largest shareholder of the company, while 6 institutions own stock in it. Virpax Pharmaceuticals Inc. Virpax Pharmaceuticals, Inc. operates as a biotech company. Not yet an official IPO, it's … Its IPO was well above the combined $136 million raised by Lava Therapeutics, Vallon Pharmaceuticals and Virpax Pharmaceuticals, which all went public during the first half 2021. Virpax is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Website popup. Malvern, PA 19355. Follow Virpax Pharmaceuticals's earnings. By Noah Smith June 14, 2021 How have the shares performed? Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray. Its products include DSF100, Probudur, Epoladerm and … The Company specializes in developing novel drug delivery systems across various pain indications. Virpax Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. VIRPAX PHARMACEUTICALS, INC. : News, information and stories for VIRPAX PHARMACEUTICALS, INC. | Nasdaq: VRPX | Nasdaq Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) loss -5.26% – Is It right time to buy? The company’s stock price has collected 7.95% of gains in the last five trading sessions. $4.3301. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Nasdaq Listed. Preclinical biotech developing new pain management drug technology. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) is registered under the ticker NASDAQ:VRPX . +0.2801 (+6.92%) DATA AS OF Jun 16, … But it's expected to go public soon. Virpax Pharmaceuticals Inc Stock Ownership Add to Watchlist. Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) | 1,498 followers on LinkedIn. Virpax Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Delivering cutting-edge eye care products. Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. The West Chester, PA-based company plans to … Contact Email Info@virpaxpharma.com Phone Number 610.727.4597 Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) went up by 1.00% from its latest closing price compared to the recent 1-year high of $8.24. The Virpax Pharmaceuticals stock patterns are available in a variety of time frames for both long and short term investments. Pennsylvania-based Virpax was founded to create new formulations for the use of existing, approved drugs for various forms of pain management applications. Virpax Pharmaceuticals filed a draft registration with the US Securities and Exchange Commission under the ticker symbol VRPX. VIRPAX PHARMACEUTICALS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Virpax Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for … Virpax Pharmaceuticals Inc. (NASDAQ:VRPX)’s Major holders. Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Press Release reported on 06/02/21 that Virpax Pharmaceuticals … MMS019 is a high-density molecular masking spray the Company is developing as an anti-viral barrier. Thani Jambulingam: Director: 2021-02-17: 100: $7.16 : $716.00 Buy. Its products include DSF100, Probudur, Epoladerm and NES100. 1 of 1. Examine the latest technical analysis for the Virpax Pharmaceuticals Inc Share. DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): Miscellaneous23.02.2021 / 14:00 The issuer is solely responsible for the content of this announcement.Virpax Begins IND Enabling Studies of Envelta(TM)WEST CHESTER, PA / ACCESSWIRE / February 23, 2021 / Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that … Virpax Pharmaceuticals Inc (NASDAQ:VRPX) has raised a total of $20.4M in funding over 3 rounds. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Stock analysis for Virpax Pharmaceuticals Inc (VRPX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. 333-253176 1,800,000 Shares Common Stock Virpax Pharmaceuticals, Inc This is a firm commitment initial public offering of 1,800,000 shares of Virpax Pharmaceuticals, Inc. common stock. The date of the filing of its original certificate of incorporation with. The Company specializes in developing novel drug delivery systems across various pain indications. Get information about Virpax Pharmaceuticals dividends and ex-dividend dates. VIRPAX PHARMACEUTICALS, INC. : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) 05/17/2021 | 04:04pm EDT *: *: * The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere … Virpax … Reinventing pain relief. The company is focused on developing pharmaceutical product candidates for pain management. Virpax Pharmaceuticals Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies to optimize and target drug delivery. 3. Name Role Date Shares Price Value; Gary S. Jacob: Director: 2021-02-17: 3,500: $6.79: $23.76k Buy. The Company is focused on developing pharmaceutical product candidates for pain management by developing and delivering non-opioid and non-addictive pharmaceutical products. Virpax Pharmaceuticals stock is not yet available to purchase on any exchange. Virpax develops branded pharmaceutical products for pain management by using cutting-edge technology to enhance patients' quality of life. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Virpax Pharmaceuticals Inc. insiders own 58.42% of total outstanding shares while institutional holders control 5.55%, with the float percentage being 13.35%. About Virpax Pharmaceuticals. Epoladermis is developed as a topical nonsteroidal anti-inflammatory drug … Virpax is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and … The company is focused on becoming a global leader in pain management by developing and delivering innovative pharmaceutical products to its customers. Virpax Pharmaceuticals is a company that develops products for pain management. Virpax Pharmaceuticals is focused on developing branded prescription products and providing more efficient drug treatments using its proprietary, cutting-edge delivery technologies designed to satisfy unmet global market needs. About Virpax Pharmaceuticals. Their latest funding was raised on Feb 16, 2021 from a Series C round. For more information, please visit www.virpaxpharma.com. For all future releases Just for the upcoming release Send me a reminder 1 trading day before. Delivering cutting-edge eye care products. Website popup. IACTA Pharmaceuticals | 135 followers on LinkedIn. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for … About Virpax Pharmaceuticals. About Virpax Pharmaceuticals. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. What we know about the Virpax Pharmaceuticals IPO. This page provides a brief financial summary of Virpax Pharmaceuticals Inc as well as the most significant critical numbers from each of its financial reports. Data is currently not available. Pennsylvania-based Virpax Pharmaceuticals (VRPX) has priced its IPO of 1.8M common shares at $10.00/share, for gross proceeds of $18M. Pennsylvania-based Virpax Pharmaceuticals has priced its IPO of 1.8M common shares at $10.00/share, for gross proceeds of $18M.Underwriters' over-allotment is … View today's stock price, news and analysis for Virpax Pharmaceuticals Inc. (VRPX). The West Chester, PA-based company plans to … The name of this corporation is Virpax Pharmaceuticals, Inc. Our Virpax Pharmaceuticals Inc (VRPX) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts Before founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Virpax Pharmaceuticals, Inc. is a biopharmaceutical company. Latest Trade: $4.86 0.00 (0.0%) First Day Return: -34.7%. Share your opinion and gain insight from other stock traders and investors. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. VRPX updated stock price target summary. Find market predictions, Virpax Pharmaceuticals Inc financial performance data and news. About Virpax Pharmaceuticals Virpax is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and … Virpax Pharmaceuticals, a preclinical biotech developing new pain management drug technology, raised $18 million by offering 1.8 million shares … Changing the way we manage pain. You can find more details by going to one of the sections under this page such as ex-date, dividend and payment date. Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): IPO19.02.2021 / 22:07 The issuer is solely responsible for the content of this announcement.Virpax Pharmaceuticals Announces Closing of Initial Public OfferingWEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in … View the VRPX U.S. Securities and Exchange Commission reporting information. Virpax® Pharmaceuticals is a publicly held company (Nasdaq: VRPX) located in Berwyn, PA and is focused on the development and commercialization of its non-addictive pipeline. About Virpax Pharmaceuticals. Delivery Method. Virpax Pharmaceuticals, a preclinical biotech developing new pain management drug technology, announced terms for its IPO on Friday. Scilex was sold to a publicly traded company. It offers a transdermal metered-dose spray, an aerosol-based system that delivers active pharmaceutical ingredients (API) as a patch-in-a-can, and liposomal in hydrogel encapsulation that provides prolonged postoperative analgesia. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. For all future releases Just for the upcoming release Send me a reminder 1 trading day before. Virpax Pharmaceuticals, a preclinical biotech developing new pain management drug technology, announced terms for its IPO on Friday. Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute … Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. 02-18 sec.gov. Delivery Method. Virpax is … Underwriters' over-allotment is … 10842745 entitled, Composition of matter comprising liposome embedded in a polymerix matrix and methods of using same. About Virpax Pharmaceuticals.